Intravitreal injections are a routine and highly effective treatment used to stabilize or restore vision in patients with diabetic eye disease, age-related macular degeneration, and retinal vein occlusions.…
Age-related macular degeneration (AMD) is the leading cause of vision loss in older Americans, affecting the central part of the retina called the macula. Alla Goldberg, MD, a…
NEW YORK (Reuters Health) – Trabeculectomy to relieve intraocular pressure (IOP) is more likely to fail if patients subsequently undergo cataract surgery, particularly if the interval between operations…
NEW YORK (Reuters Health) – Canaloplasty works just as well as trabeculectomy in reducing intraocular pressure (IOP) in patients with open-angle glaucoma, according to results of a retrospective…
NEW YORK (Reuters Health) – An intraocular lens made of a photoreactive silicone material can be adjusted using ultraviolet irradiation after being implanted following cataract removal, providing individual…
NEW YORK (Reuters Health) – Despite tradeoffs in visual acuity, patients with ocular melanoma near the optic nerve benefit from proton beam radiotherapy in terms of eye conservation…
NEW YORK (Reuters Health) – Some patients with primary open-angle glaucoma benefit from more frequent visual field testing, according to results of a study published online August 8…
NEW YORK (Reuters Health) – Despite changes in the flora responsible for microbial keratitis, second-generation fluoroquinolone monotherapy remains the empirical treatment of choice, researchers from the UK report…
NEW YORK (Reuters Health) – Resolution of pain and inflammation after cataract surgery is faster when patients are treated once a day with bromfenac ophthalmic solution, according to…
NEW YORK (Reuters Health) – As a first-line operation for primary open-angle glaucoma, insertion of a Molteno drainage tube provides better control of intraocular pressure (IOP) than does…
NEW YORK (Reuters Health) – After six monthly intraocular injections of ranibizumab (Lucentis; Genentech) for macular edema, the benefits are maintained for another 6 months when ranibizumab is…
